Jeh Aerospace's current orderbook has exceeded $150 million in just 18 months, underscoring strong global demand for its precision components.
Sudeep Pharma IPO | The company approached capital markets with the aim to mobilise Rs 895 crore via initial public offering (IPO) at the upper end of price band of Rs 563-593 per share.
Gallard Steel IPO | The cast components maker has tapped capital markets to raise Rs 37.5 crore via initial public offering (IPO) of 25 lakh shares at the upper end of price band of Rs 142-150 per share.
SSMD Agrotech IPO | The Delhi-based company, which operates under the brand House of Manohar, aims to raise Rs 33.8 crore via initial public offering of 28.17 lakh shares at the upper price band.
Since taking charge as MD & CEO of API Holdings parent of PharmEasy in August, Rahul Guha is pivoting the group from growth-at-any-cost to profit-first execution, tightening costs, rejigging capital, and pushing higher‑margin products and services across the ecosystem.
The goal of fostering a fair and equitable marketplace remains common unless repeated violations become collateral damage. CCI penalised FPBAI for anti-competitive practices, reinforcing India’s strengthened competition law and stricter enforcement powers
The accused, identified as Gadi Manikanta and Yendapalli Jessy Sudarshan, allegedly impersonated USFDA officials using fake email IDs and encrypted messaging apps, including Signal, to pressure Hetero, a release issued by Cyberabad police said.
Gallard Steel IPO | The company entered capital markets to raise Rs 37.5 crore via its initial share sale of 25 lakh shares at the upper end of price band of Rs 142-150 per share.
These drugs promise faster results with fewer side effects, and in some cases, reversal or slows the disease progression.
Excelsoft Technologies IPO | The Rs 500-crore initial share sale will open for public subscription on November 19, with price band of Rs 114-120 per share, and close on November 21.
Gallard Steel IPO | The company approached capital markets to mop up Rs 37.5 crore via initial public offering (IPO) of 25 lakh shares at the upper end of price band of Rs 142-150 per share.
Sudeep Pharma IPO | The company will open its Rs 895 crore IPO for the public on November 21 and close on November 25, while the anchor book will be launched for a day on November 20.
Milestone Gears IPO | The company has proposed to issue fresh shares worth Rs 800 crore, and its promoters and other selling shareholder will be selling Rs 300 crore worth shares via offer-for-sale.
Mankind Pharma CEO Sheetal Arora has attributed the slowdown to GST 2.0 disruptions and uneven monsoon.
Sudeep Pharma IPO | The company is set to raise Rs 95 crore by issuing fresh shares, while promoters will offload 1.34 crore equity shares via offer-for-sale.
Upcoming IPO: The SEBI has issued observations on the draft document of Acevector, and Steel Infra Solutions Company on November 11, followed by Silver Consumers Electricals on November 12.
Under the agreement, AstraZeneca will sell SZC under the brand Lokelma, while Sun Pharma will distribute it as Gimliand.
Wakefit IPO | It is a part of pre-IPO placement worth Rs 93.6 crore planned by the company at the time of filing of draft document with the SEBI.
Genesys' revenue from operations rose 6.8 percent to Rs 76.94 crore in Q2 FY26, as compared to Rs 72 crore in Q2 FY25.
Sky Gold and Diamond said total income increased to Rs 1,492.45 crore during the quarter, from Rs 788.59 crore in the year ago period.
Gallard Steel IPO | The company aims to mop up Rs 37.5 crore via initial public offering of 25 lakh shares at the upper price band.
A selection of articles and social media gems from the world of economy, business and finance, curated by our research and opinion teams
Awfis is also expanding across both metros and Tier II markets, with operations in nine metros and nine Tier II cities. Ramani said growth in Tier II has been strong, though supply availability is a constraint.
Capillary Technologies IPO | The Bengaluru-based company aims to mobilise Rs 877.5 crore via initial public offering (IPO) which is a mix of fresh issuance of shares worth Rs 345 crore, and an offer-for-sale of 92.28 lakh shares amounting to Rs 532.5 crore by promoter Capillary Technologies International, and investor Trudy Holdings.
Global biosimilar development typically costs between $100 million and $200 million, but the U.S. Food and Drug Administration’s updated recommendations aim to eliminate expensive comparative efficacy studies, relying instead on advanced analytical and pharmacokinetic data.
